Pharmacoepidemiology Treatment of Symptomatic Pulmonary Embolism in Hospitalized Patients Aged 75 Years or More: PEAGE

  • End date
    Jun 18, 2022
  • participants needed
  • sponsor
    Centre Hospitalier Universitaire de Saint Etienne
Updated on 18 April 2021
Primary Contact
CHU Gabriel Montpied (0.0 mi away) Contact
+24 other location
vitamin k antagonist
vitamin k
venous thromboembolic disease


The treatment of the venous thromboembolic disease, including pulmonary embolism (PE), is based on anticoagulants. During the last decade, all the randomized clinical trials evaluating these anticoagulants have included PE patients with an average age below 60 years. But in clinical pratice, approximately 50% of PE patients are older than 75 years.

So the investigators want to perform a french multicentre prospective cohort of consecutive patients receiving an anticoagulant treatment for a symptomatic and confirmed PE. All the validated and available anticoagulant treatments are authorized in this cohort (unfractionnated and low molecular weight heparins, fondaparinux, vitamin K antagonists and direct oral anticoagulants).

This cohort will provide data regarding the bleeding risk and the risk of PE recurrences and regarding the pharmacokinetic (PK) and pharmacodynamic (PD) properties of these anticoagulants in this older population. Using population approach modelling , the investigators will pay particular attention to the sources of PK/PD variability PK / PD such as genetic polymorphisms of P-glycoprotein and cytochrome P450.

Using all these data , the investigators will try to identify significant risk factors for bleeding and venous thromboembolic events.

Condition Pulmonary Disease, Anticoagulants, Pulmonary Embolism, Aged, Lung Disease, anticoagulant, blood thinner, agents, anticoagulant, anticoagulation agents, blood thinners, anticoagulant drugs, lung embolism
Treatment 4 blood samples
Clinical Study IdentifierNCT02360943
SponsorCentre Hospitalier Universitaire de Saint Etienne
Last Modified on18 April 2021


Yes No Not Sure

Inclusion Criteria

Symptomatic pulmonary embolism confirmed by objective paraclinical examination with or without DVT associated
confirmation of pulmonary embolism within 3 days
Administration possible according to the recommended dosages of anticoagulant treatment : (unfractionnated and low molecular weight heparins, fondaparinux, vitamin K antagonists and direct oral anticoagulants)
Indication of anticoagulant treatment for at least 6 months

Exclusion Criteria

on therapeutic dose of anticoagulant treatment over 72 hours
indication to therapeutic dose of anticoagulant treatment for another reason
Inability for whatever reasons, to prescribe recommended anticoagulant treatment
PE treatment on heparin-induced thrombocytopenia requiring argatroban, lepirudin or danaparoid treatment
ongoing bleeding
PE occurring despite well conducted anticoagulant treatment
Contraindications to recommended dose of anticoagulant treatment
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note